Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
September 20, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents...
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
September 05, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
August 30, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
July 31, 2023 16:05 ET
|
Portage Biotech, Inc.
Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led programUpdated...
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
June 26, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and...
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
June 05, 2023 08:00 ET
|
Portage Biotech, Inc.
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on the favorable safety and tolerability data at all doses tested...
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
June 01, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and...
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023 17:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents...
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents...
Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
March 01, 2023 08:00 ET
|
Portage Biotech, Inc.
- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 -...